Associated Genetic Biomarkers
Calreticulin (CALR) is a calcium-binding protein that functions in calcium storage and transcription regulation. Missense mutations, silent mutations, nonsense mutations, and frameshift insertions and deletions are observed in cancers such as colorectal cancer, leukemias, myeloproliferative neoplasms, and stomach cancer.
CALR is altered in 0.84% of all cancers with myelofibrosis, lung adenocarcinoma, breast invasive ductal carcinoma, high grade ovarian serous adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in CALR are CALR Mutation (0.51%), CALR Amplification (0.15%), CALR L367fs (0.09%), CALR L367Tfs*46 (0.09%), and CALR K385fs (0.04%) .
CALR status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain CALR status as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open).
Trials with CALR status in the inclusion eligibility criteria most commonly target myelofibrosis and secondary acute myeloid leukemia .
The most frequent alteration to serve as an inclusion eligibility criterion is CALR Mutation .
Allogeneic hematopoietic stem cell transplantation, busulfan, cyclophosphamide, fludarabine, and liposome-encapsulated daunorubicin-cytarabine are the most frequent therapies in trials with CALR as an inclusion criteria .
Significance of CALR in Diseases
Multiple Myeloma +
CALR is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains CALR status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) .
Plasma Cell Leukemia +
CALR is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains CALR status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) .
Secondary Acute Myeloid Leukemia +
CALR is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CALR status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.